KR20220148867A - (R)-N-(3-플루오로-4-((3-((1-히드록시프로판-2-일)아미노)-1H-피라졸로[3,4-b]피리딘-4-일)옥시)페닐)-3-(4-플루오로페닐)-1-이소프로필-2,4-디옥소-1,2,3,4-테트라히드로피리미딘-5-카르복스아미드를 사용하여 암을 치료하는 방법 - Google Patents

(R)-N-(3-플루오로-4-((3-((1-히드록시프로판-2-일)아미노)-1H-피라졸로[3,4-b]피리딘-4-일)옥시)페닐)-3-(4-플루오로페닐)-1-이소프로필-2,4-디옥소-1,2,3,4-테트라히드로피리미딘-5-카르복스아미드를 사용하여 암을 치료하는 방법 Download PDF

Info

Publication number
KR20220148867A
KR20220148867A KR1020227033740A KR20227033740A KR20220148867A KR 20220148867 A KR20220148867 A KR 20220148867A KR 1020227033740 A KR1020227033740 A KR 1020227033740A KR 20227033740 A KR20227033740 A KR 20227033740A KR 20220148867 A KR20220148867 A KR 20220148867A
Authority
KR
South Korea
Prior art keywords
compound
cancer
administered
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227033740A
Other languages
English (en)
Korean (ko)
Inventor
캐린 수 부하나
짐 육-파이 웡
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20220148867A publication Critical patent/KR20220148867A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227033740A 2020-03-03 2021-03-01 (R)-N-(3-플루오로-4-((3-((1-히드록시프로판-2-일)아미노)-1H-피라졸로[3,4-b]피리딘-4-일)옥시)페닐)-3-(4-플루오로페닐)-1-이소프로필-2,4-디옥소-1,2,3,4-테트라히드로피리미딘-5-카르복스아미드를 사용하여 암을 치료하는 방법 Withdrawn KR20220148867A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062984458P 2020-03-03 2020-03-03
US62/984,458 2020-03-03
US202163133501P 2021-01-04 2021-01-04
US63/133,501 2021-01-04
PCT/IB2021/051693 WO2021176330A1 (en) 2020-03-03 2021-03-01 Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

Publications (1)

Publication Number Publication Date
KR20220148867A true KR20220148867A (ko) 2022-11-07

Family

ID=74860342

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227033740A Withdrawn KR20220148867A (ko) 2020-03-03 2021-03-01 (R)-N-(3-플루오로-4-((3-((1-히드록시프로판-2-일)아미노)-1H-피라졸로[3,4-b]피리딘-4-일)옥시)페닐)-3-(4-플루오로페닐)-1-이소프로필-2,4-디옥소-1,2,3,4-테트라히드로피리미딘-5-카르복스아미드를 사용하여 암을 치료하는 방법

Country Status (12)

Country Link
US (1) US20230117328A1 (enExample)
EP (1) EP4114397A1 (enExample)
JP (2) JP7181325B2 (enExample)
KR (1) KR20220148867A (enExample)
CN (1) CN115529816A (enExample)
AU (1) AU2021231435A1 (enExample)
BR (1) BR112022017267A2 (enExample)
CA (1) CA3174064A1 (enExample)
IL (1) IL296060A (enExample)
MX (1) MX2022010955A (enExample)
TW (2) TWI775333B (enExample)
WO (1) WO2021176330A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023002360A1 (en) * 2021-07-22 2023-01-26 Pfizer Inc. Solid forms and formulations of an inhibitor of tam and c-met kinases
CN122140719B (zh) * 2026-04-15 2026-07-28 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Sgi-7079在治疗flt3突变型急性髓系白血病中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US10195208B2 (en) * 2014-07-31 2019-02-05 Novartis Ag Combination therapy
WO2016019270A1 (en) 2014-07-31 2016-02-04 Academia Sinica An antagonistic pd-1 aptamer and its applications in cancer therapy related applications
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met

Also Published As

Publication number Publication date
CN115529816A (zh) 2022-12-27
TW202317125A (zh) 2023-05-01
JP2023009250A (ja) 2023-01-19
TWI814504B (zh) 2023-09-01
BR112022017267A2 (pt) 2022-12-13
WO2021176330A1 (en) 2021-09-10
IL296060A (en) 2022-10-01
AU2021231435A1 (en) 2022-09-22
MX2022010955A (es) 2022-10-07
JP2021138693A (ja) 2021-09-16
EP4114397A1 (en) 2023-01-11
JP7181325B2 (ja) 2022-11-30
TWI775333B (zh) 2022-08-21
US20230117328A1 (en) 2023-04-20
TW202146025A (zh) 2021-12-16
CA3174064A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
JP2023145689A (ja) Ｈｅｒ２陽性がんの処置
EP2882440B1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
RU2607596C2 (ru) Комбинированная противораковая терапия
BR112019021880A2 (pt) Terapia de combinação com conjugado anticorpo anti-axl-droga
BR112015026297B1 (pt) Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
JP2026079825A (ja) 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害
CN109890386A (zh) 药物组合
JP2023009250A (ja) がんを処置するための方法
CN109073650A (zh) 包括对西地尼布进行固定的间歇给药的方法
HK40079302A (en) Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
CA3087844A1 (en) Methods and combination therapy to treat cancer
JP2023539506A (ja) 非小細胞肺がんの治療における抗ｐｄ－１抗体及び細胞毒性抗がん剤の用途
WO2024263960A2 (en) Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263801A2 (en) Compositions comprising antineoplastons and methods of treating ovarian cancer
EP4731793A2 (en) Compositions comprising antineoplastons and methods of treating pancreatic cancer
EP4731199A2 (en) Compositions comprising antineoplastons and methods of treating colorectal cancer
WO2024263643A1 (en) Compositions comprising antineoplastons and methods of treating breast cancer
WO2024263972A2 (en) Compositions comprising antineoplastons and methods of treating uncommon cancers
WO2026103822A1 (zh) Ras抑制剂和pd-1或pd-l1抑制剂的组合及其用途
US20190211102A1 (en) Methods and combination therapy to treat cancer
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
WO2021142237A1 (en) Methods for administering lucitanib and combinations thereof
CN114667159A (zh) 喹啉衍生物与pd-1单抗的药物组合
HK40028739A (en) Methods and combination therapy to treat cancer

Legal Events

Date Code Title Description
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202